Interferon-Gamma Inducible Protein 10 (IP-10) Sebelum Pengobatan Berhubungan dengan Kekambuhan Pada Tubekulosis Resisten Obat
Statistik artikel
Data OJS dan sumber sitasiTayangan dan unduhan adalah aktivitas yang tercatat di OJS; pemrosesan statistik dapat tertunda. Tanda — berarti angka dari sumber tersebut belum tersedia. Cari di Google Scholar
Isi Artikel Utama
Abstrak
Latar Belakang: IP-10 ditemukan pada kadar tinggi pada pasien tuberkulosis resisten obat (TB-RO). Studi ini menganalisis kadar IP-10 sebelum pengobatan dan hubungannya pada pasien TB-RO yang kambuh. Metode: Penelitian ini menggunakan desain kasus-kontrol. Pasien TB-RO dibagi menjadi kelompok kontrol yang terdiri dari pasien yang baru dan kelompok kasus yang terdiri dari pasien yang kambuh. Kadar IP-10 diukur menggunakan metode sandwich ELISA. Uji Mann-Whitney digunakan untuk menganalisis perbedaan kadar IP-10 antara kedua kelompok. Hasil: 72 pasien TB-RO ikut serta dalam studi ini, dan 45 (62,5%) di antaranya adalah kasus kambuh. Median (IQR) IP-10 lebih tinggi pada kasus kambuh dibandingkan dengan kasus baru, yaitu 1876,4 (625,2-8313) vs 1304 (590,4-2001) pg/ml, dengan P-value < 0,001. Di antara kasus kambuh, pasien dengan kavitas paru memiliki kadar IP-10 yang lebih tinggi dibandingkan dengan yang tanpa kavitas, P-value < 0,001. Berdasarkan kurva ROC, nilai ambang optimal IP-10 adalah 1555,6 pg/mL, dengan sensitivitas dan spesifisitas 66,7% dalam memprediksi kasus kambuh. Kadar IP-10 sebelum pengobatan ≥ 1555,6 pg/ml secara signifikan berhubungan dengan kasus kembuh (OR = 3,625; 95% CI: 1,325-9,917), dan tingkat IP-10 ≥ 2012,4 pg/ml secara signifikan berhubungan dengan kavitas paru pada pasien DR-TB yang kambuh (OR = 7,429; 95% CI: 1,939-28,466). Kadar IP-10 berkorelasi dengan tingkat positif BTA (P-value=0,010; Spearman rho=0,506) pada pasien TB-RO yang kambuh. Kesimpulan: Kadar IP-10 secara signifikan lebih tinggi pada pasien TB-RO yang kambuh dan yang memiliki kavitas paru. Kadar IP-10 ≥ 1555,6 pg/ml berhubungan dengan terjadinya kasus kambuh. Kadar IP-10 ≥ 2012,4 pg/ml secara signifikan berhubungan dengan kavitas paru pada kasus kambuh.
Rincian Artikel
Terbitan
Bagian

Artikel ini berlisensiCreative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Cara Mengutip
Referensi
[1]. World Health Organization. Global tuberculosis report 2024. World Health Organization; 2024.
[2]. Sinulingga HE, Sinaga BYM, Siagian P, Ashar T. Profile and risk factors of pre-XDR-TB and XDR-TB patients in a national reference hospital for Sumatra region of Indonesia. Narra J. 2023;3:7-12
[3]. Wotale TW, Lelisho ME, Negasa BW, Tareke SA, Gobena WE, Amesa EG. Identifying risk factors for recurrent multidrug resistant tuberculosis based on patient’s record data from 2016 to 2021: retrospective study. Sci Rep. 2024;14:23912
[4]. Youn HM, Shin MK, Jeong D, Kim HJ, Choi H, Kang YA. Risk factors associated with tuberculosis recurrence in South Korea determined using a nationwide cohort study. PLoS One. 2022;17:e0268290
[5]. Shanmuganathan G, Orujyan D, Narinyan W, Poladian N, Dhama S, Parthasarathy A, et al. Role of Interferons in Mycobacterium tuberculosis Infection. Clin Pract. 2022;12:788–96.
[6]. Le Y, Cao W, Zhou L, Fan X, Liu Q, Liu F, et al. Infection of Mycobacterium tuberculosis Promotes Both M1/M2 Polarization and MMP Production in Cigarette Smoke-Exposed Macrophages. Front Immunol. 2020;11:1902
[7]. Efriyani YI, Parwati I, Tristina N, Tjandrawati A. IP-10 as a Non Sputum Biomarker in TB Treatment Monitoring. Majalah Kedokteran Bandung. 2021;53:17-21
[8]. Alisjahbana B, Sulastri N, Livia R, Apriani L, Verrall AJ, Sahiratmadja E. Neutrophils and lymphocytes in relation to MMP-8 and MMP-9 levels in pulmonary tuberculosis and HIV co-infection. J Clin Tuberc Other Mycobact Dis. 2022;27:100308
[9]. Ali ZA, Mankhi AA, Ad’hiah AH. Significance of the chemokine CXCL10 and human beta-defensin-3 as biomarkers of pulmonary tuberculosis. Tuberculosis. 2021;128:102078
[10]. Strzelak A, Komorowska-Piotrowska A, Borowa A, Krasińska M, Feleszko W, Kulus M. IP-10 for the Diagnosis and Treatment Monitoring of Tuberculosis in Children. Diagnostics. 2024 ;14:177
[11]. Muchsin S, Priyanto H, Zulfikar T, Kurniawan FD. The Difference in Serum Levels of IP-10 in Patients with Pulmonary Tuberculosis with A Positive AFB and AFB Conversion. Jurnal Respirologi Indonesia. 2022 ;42:18-24
[12]. Setyawan MF, Mertaniasih NM, Soedarsono S, Nuha Z, Maladan Y, Matsumoto S. Mycobacterium tuberculosis-AtpE gene profile of bedaquiline-Treated pulmonary tuberculosis patients at the referral hospital Dr. Soetomo, Indonesia. Int J Mycobacteriol. 2023;12:122–8.
[13]. Khan AS, Phelan JE, Khan MT, Ali S, Qasim M, Napier G, et al. Characterization of rifampicin-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan. Sci Rep. 2021;11:14194
[14]. Putra ON, Yulistiani Y, Soedarsono S, Subay S. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review. Int J Mycobacteriol. 2023;12:1-9
[15]. Bade AB, Mega TA, Negera GZ. Malnutrition is associated with delayed sputum culture conversion among patients treated for mdr-tb. Infect Drug Resist. 2021;14:1659–67.
[16]. Li S, Liang Y, Hu X. Risk factors for multidrug resistance in tuberculosis patients with diabetes mellitus. BMC Infect Dis. 2022;22:835
[17]. Araia ZZ, Mesfin AB, Mebrahtu AH, Tewelde AG, Osman R, Tuumzghi HA. Diabetes mellitus and its associated factors in tuberculosis patients in Maekel region, Eritrea: Analytical cross-sectional study. Diabetes Metab Syndr Obes. 2021;14:515–23.
[18]. Kassa GM, Merid MW, Muluneh AG, Fentie DT. Sputum smear grading and associated factors among bacteriologically confirmed pulmonary drug-resistant tuberculosis patients in Ethiopia. BMC Infect Dis. 2021;21:238
[19]. Urbanowski ME, Ordonez AA, Ruiz-Bedoya CA, Jain SK, Bishai WR. Cavitary tuberculosis: the gateway of disease transmission. Lancet Infect Dis. 2020;20:e117–28.
[20]. Pradana RF, Nawawi YS, Satoto B. Chest X-Ray Evaluation of Cavitary Lesions among Pulmonary MDR-TB Patients. eJKI. 2018;6:1–4.
[21]. Chen L, Zhang J, Zhang H. A large pulmonary cavity replaced by a tuberculosis granuloma and healed during treatment of a patient with tuberculosis. J Infect Dev Ctries. 2018;12:60–2.
[22]. Sampath P, Rajamanickam A, Thiruvengadam K, Natarajan AP, Hissar S, Dhanapal M, et al. Plasma chemokines CXCL10 and CXCL9 as potential diagnostic markers of drug-sensitive and drug-resistant tuberculosis. Sci Rep. 2023;13:7404
[23]. Mutavhatsindi H, Manyelo CM, Snyders CI, Rensburg IV, Kidd M, Stanley K., et al. Baseline and end-of-treatment host serum biomarkers predict relapse in adults with pulmonary tuberculosis. J Infect. 2024;89:106173
[24]. Petrone L, Bondet V, Vanini V, Cuzzi G, Palmieri F, Palucci I, et al. International Journal of Infectious Diseases First description of agonist and antagonist IP-10 in urine of patients with active TB. Int J Infect Dis. 2019;78:15–21
[25]. Aravindhan V, Kevinkumar V, Dhamodharan U, Viswanathan V. Serum levels of chemokines IP-10, IL-8 and SDF-1 serve as good biomarkers for diabetes-tuberculosis nexus. J Diabetes Complications. 2018;32:857–62.
[26]. Mvo S, Bokop C, Longo-Mbenza B, Vasaikar SD, Apalata T. Prolongation of Acid-Fast Bacilli Sputum Smear Positivity in Patients with Multidrug-Resistant Pulmonary Tuberculosis. Pathogens. 2023;12:1133
[27]. Rahmasena N, Marhana IA, Suwandi MYS, Kusmiati T, Jearanaiwitayakul T. Factors Associated with Acid Fast Bacilli and Sputum Culture Conversion in Patients with Multidrug-Resistant Tuberculosis in Surabaya. Biomolecular and Health Science Journal. 2021;4:107.





